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Abstract 
Background & Aims: Several strategies are available for detecting cirrhosis in patients with non-
alcoholic fatty liver disease (NAFLD), but their cost effectiveness is not clear. We developed a 
decision model to quantify the accuracy and costs of 9 single or combination strategies, including 3 
noninvasive tests (fibrosis-4 [FIB-4], vibration controlled transient elastography [VCTE], and 
magnetic resonance elastography [MRE]) and liver biopsy, for detection of cirrhosis in patients 
with NAFLD.  
Methods: Data on diagnostic accuracy, costs, adverse events, and cirrhosis outcomes over a 5-y 
period were obtained from publications. The diagnostic accuracy, per-patient cost per correct 
diagnosis of cirrhosis, and incremental cost-effectiveness ratios (ICER) were calculated for each 
strategy for base cirrhosis prevalence values of 0.27%, 2%, and 4%. 
Results: The combination of the FIB-4 and VCTE identified patients with cirrhosis in NAFLD 
populations with a 0.27%, 2%, and 4% prevalence of cirrhosis with the lowest cost per person 
($401, $690, and $1024, respectively) and highest diagnostic accuracy (89.3%, 88.5%, and 87.5% 
respectively). The combination of FIB-4 and MRE ranked second in cost per person ($491, $781, 
and $1114, respectively) and diagnostic accuracy (92.4%, 91.6%, 90.6%, respectively).  Compared 
to the combination of FIB-4 and VCTE (least costly), the ICERs were lower for the combination of 
FIB-4 and MRE ($2864, $2918, and $2921) than the combination of FIB-4 and liver biopsy ($4454, 
$5156, and $5956) at the cirrhosis prevalence values tested. When goal was to avoid liver biopsy, 
FIB-4+VCTE and FIB-4+MRE had similar diagnostic accuracies, ranging from 87.5% to 89.3% 
and 90.6% to 92.4% for cirrhosis diagnosis, although FIB-4+MRE had a slightly higher cost. 
Conclusions: In our cost effectiveness analysis based on United States health care system, we 
found that results from FIB-4, followed by either VCTE, MRE, or liver biopsy, detect cirrhosis in 
patients with NAFLD with a high level of accuracy and low cost. Compared to FIB-4 + VCTE 
which was the least costly strategy, FIB-4+MRE had lower ICER than FIB-4+LB. 
KEY WORDS: comparison, expense, sensitivity, imaging, biomarker 
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What You Need to Know 
Background: Several methods are available for detecting cirrhosis in patients with non-alcoholic 
fatty liver disease (NAFLD), but little is known about their cost effectiveness.  
Findings: In an analysis of data from publications, we found that FIB-4, followed by either VCTE, 
MRE, or liver biopsy, detects cirrhosis in patients with NAFLD with a high level of accuracy and 
low cost. However, the combination of FIB-4 and liver biopsy has a higher ICER, compared to the 
combination of FIB-4 and VCTE or FIB-4 and MRE.  
Implications for patient care: The FIB-4, in combination with VCTE, MRE or liver biopsy, 
identifies patients with NAFLD who have cirrhosis accurately and cost effectively. 
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INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, 
hepatocellular carcinoma (HCC), and liver transplantation.1 The extent of hepatic fibrosis is the 
strongest risk factor for long-term complications; patients with advanced fibrosis are at the highest 
risk of hepatic decompensation, HCC, and cardiovascular disease.2 Thus, accurate staging of 
fibrosis is necessary for proper management of patients with NAFLD, both for estimating prognosis 
and guiding therapy. While liver biopsy (LB) is the gold standard for staging liver fibrosis and 
diagnosing cirrhosis, it is invasive, costly, and has technical limitations, including sampling error 
and variation in histological interpretation, making it impractical as a routine screening or 
diagnostic tool.  
Several non-invasive tests (NITs) are available for staging liver fibrosis, including blood-
based biomarkers (Fib-4)3, and modalities that assess liver stiffness such as vibration controlled 
transient elastography (VCTE)4 and magnetic resonance elastography (MRE).5 Most NITs are good 
at excluding advanced fibrosis (negative predictive value > 90%), but sensitivity is lower for 
detecting advanced fibrosis.6-8 Among the modalities assessing liver stiffness, VCTE is the most 
widely studied and validated method, yielding good intra- and inter-observer variability and low 
failure rates.4 Moreover, its wide availability and easy-to-operate feature make VCTE a potential 
point-of-care test. Most recently, 2D- and 3D-MRE have emerged as promising noninvasive tests 
for diagnosing advanced fibrosis in NAFLD patients. MRE and VCTE have high accuracy in 
identifying advanced fibrosis.8 The Fib-4 index is a simple and inexpensive blood-based panel that 
is useful for excluding advanced fibrosis.3 It has been extensively validated in patients with 
NAFLD. Fib-4 cutoffs ≥ 3.25 or ≤ 1.30 have 80% and 90% positive and negative predictive values, 
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respectively, for detecting or excluding advanced fibrosis among patients CLD, including NAFLD.7 
Its major limitation is that a high proportion of values fall in the indeterminate range (1.30-3.25).7 
In clinical practice, a sequential combination of two NITs may improve the detection of 
patients with advanced fibrosis and reduce the number of patients with indeterminate results;9, 10 
however, its cost-effectiveness has not been fully explored. Herein, we developed a decision model 
to quantify the accuracy and costs of various non-invasive strategies for diagnosing cirrhosis in 
NAFLD patients to understand better which strategies might be considered preferable in clinical 
practice.      
METHODS 
Study population 
Our study population consists of a hypothetical cohort of middle-aged patients with NAFLD 
seen in three different settings: (a) in a specialty clinic setting where the prevalence of cirrhosis in 
NAFLD is estimated to be 2%11, (b) in a general population-based setting where the prevalence of 
cirrhosis is estimated to be 0.27%12 and tertiary referral centers setting where cirrhosis prevalence is 
reported to be ≈4%.5, 7, 8 
Model structures 
We constructed a decision model to compare the accuracy and costs associated with liver 
biopsy and NITs alone and in a sequential combination for the diagnosis of cirrhosis. We 
considered Fib-4 and liver stiffness measured by VCTE or MRE, and assumed that liver biopsy, as 
the reference standard, would have the highest sensitivity and specificity for cirrhosis. Test 
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accuracy for each strategy was calculated as follows: (true positive (TP) + true negative (TN))/(total 
population). To evaluate the ensuing clinical events for future costs and outcomes; we attached a 
microsimulation to each leaf node of the decision tree to emulate subsequent clinical events over a 
5-year time horizon. Figures 1A-C summarize the decision tree of the nine diagnostic strategies
and the transitions in the microsimulation of patients after receiving a diagnosis of cirrhosis. 
In the decision-tree portion of the model, we considered each test individually and in 
clinically appropriate combinations where either stiffness-based method was added sequentially to 
Fib-4 or where LB was added sequentially to either a stiffness-based method or Fib-4. For all test 
strategies, a positive test may suggest cirrhosis. Additionally, failure rates for VCTE (7.1%)4, 13 and 
MRE (4%)14, 15, and indeterminate results for Fib-4 (32%)4 were included. For combination 
strategies, a second test was added if the initial test was either positive or indeterminate for Fib-4, or 
uninterpretable for VCTE/MRE. The result of the second test determined the final diagnosis of 
cirrhosis. Finally, a do-nothing approach was included along with all test strategies.   
We assumed that all patients with cirrhosis diagnosis underwent periodic guideline-based 
screening for esophageal varices (EV) and HCC16, 17 over a 5-year period. The disease state and 
mortality status were updated during the 5-year period. As a result, costs of the periodic screening 
for EVs and HCC were accumulated over the 5-year period. For those who tested positive, the costs 
include: (1) periodic EV screening [every 2 years if EV is small and at 3-year intervals if EVs are 
absent],17 (2) HCC screening every 6 months using serum α-fetoprotein and ultrasound,16 (3) 
primary prophylaxis of EV bleeding with both endoscopic band ligation (EBL) and nonselective 
beta-blockers (NSBB),17 (4) outpatient clinic visit and (5) those derived from liver transplantation 




We performed a sensitivity analysis by varying the prevalence range from 0.27% to 4%. The 
prevalence of EV among cirrhotics was estimated to be 34.7%.18 We considered the annual 
incidence of EV and HCC to be 2.3% (unpublished data from Indiana University Medical Center) 
and 2.5%, respectively.2 The pooled 3-year HCC mortality rate is 49.2% among patients undergoing 
HCC surveillance vs 72.1% among those without periodic surveillance.16 W  assumed a 16.3% 6-
month risk of mortality due to variceal bleeding.19  We considered a prevalence of 11.5% of large or 
high-risk varices among compensated NAFLD cirrhotics.20 and assumed that 34% of small or no 
varices would progress to large varices at 3 years.21 The pooled 2-year risk of upper gastrointestinal 
bleeding is 17% 22 and 31% 23 among patients with or without primary prophylaxis including both 
EBL and/or NSSB. Table 1, Figure 1C and supplemental Tables 1-3 summarize some of the 
above-mentioned parameters used in the model. 
An institutional cost perspective was adopted, expressed in 2017 U.S. dollars. Direct costs 
for LB, MRE and VCTE were obtained from Medicare reimbursement data (supplemental Table 
4). 
Analysis 
We simulated the costs for a particular strategy, which included the costs of (1) each 
diagnostic strategy, (2) HCC and EV screenings, (3) periodic clinic visits, (4) management of LB-
related complications (i.e., bleeding) and (5) liver transplantation or HCC-related liver resection. 
We also simulated the diagnostic accuracy for a particular strategy. Diagnostic accuracy was 
defined as the percentage of correct diagnosis, which equals the sum of numbers of people who 
were correctly identified with or without cirrhosis (excluding the numbers after the confirmation 
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test), divided by the total population. We next calculated the cost per correct diagnosis, which was 
used as a proxy in the ensuing cost-effectiveness analysis. We lastly calculated the incremental 
cost-effectiveness ratios (ICERs) and cost per death prevented (CPDP). ICERs were defined as the 
incremental cost for each additional correct diagnosis (see supplemental material): the strategies 
were sorted by ascending order of cost, and the current least costly strategy was compared with the 
previous least costly strategy. If the accuracy of the current least costly strategy was lower than the 
previous one, then the current strategy was considered dominated. CPDP was calculated using the 
same logic, and we used mortality instead of diagnostic accuracy.  
We further plotted per-patient total cost and diagnostic accuracy, and per-patient total cost 
and mortality for each strategy. Any strategy, such that no other strategies would yield lower cost 
and higher accuracy (lower mortality) simultaneously, was considered to be a dominant strategy. In 
the presence of more than one dominant strategy, the dominant strategies formed an efficiency 
frontier; strategies below and to the right of the frontier were considered to be dominated.  
To assess the robustness of model results, we performed sensitivity analyses on cirrhosis 
prevalence (0%-12%). In addition, we performed one-way sensitivity analyses on test 
characteristics and costs with cirrhosis prevalence being fixed at 0.27%.  
RESULTS 
Base case. 
Low prevalence of cirrhosis (0.27%). Fib-4 alone correctly classifies the lowest percentage of 
persons (57%), while Fib-4+LB correctly classified 97.7%, the highest percentage (T ble 2). 
Figure 2A shows diagnostic accuracy by cost per person for each strategy. The solid line represents 
the efficiency frontier, which identifies strategies with the lowest cost and highest accuracy, and 
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includes: Fib-4+VCTE (89.3%, $401), Fib-4+MRE (92.4%, $491) and Fib-4+LB (97.7%, $729). 
Relative to Fib-4+VCTE, which is the least costly strategy with 89.3% accuracy, ICERs for the 
frontier strategies range from $2,864 per additional correct diagnosis for Fib-4+MRE to $4,454 for 
Fib-4+LB (Table 2). Figure 2B and supplemental Table 5 display mortality by cost per person for 
each strategy. Compared to do-nothing strategy, which yields highest mortality (46 deaths) and 
lowest cost ($10), Fib-4+VCTE (41 deaths, $401), VCTE+LB (39 deaths, $613), VCTE (38 deaths, 
$901) and LB (36 deaths, $1663) show the best combination of cost versus mortality.  
Supplemental Tables 6-14 depict detailed results on diagnostic accuracy for all strategies. 
Intermediate prevalence of cirrhosis (2%). Both the cost per person for each strategy and the cost 
per correct diagnosis per person are higher for an intermediate prevalence of cirrhosis as compared 
with low cirrhosis prevalence. Fib-4 alone remains the least accurate strategy (56.5%). Base results 
for intermediate cirrhosis prevalence closely parallel results for low prevalence with the same three 
least costly strategies which are Fib-4+VCTE (88.5% accuracy, cost of $690), Fib-4+MRE (91.6%, 
$781), and Fib-4+LB (97%, $1,060) (Table 3). VCTE+LB has the same cost than Fib-4+LB, but it 
yields lower diagnostic accuracy (Table 3 and Figure 2C). Figure 2C shows 3 strategies on the 
efficiency frontier, including the three same frontier strategies for the low prevalence case, with 
ICERs ranging from $2,918 (Fib-4+MRE) to $5,156 (Fib-4+LB) per additional correct diagnosis 
(Table 3). Results based on cost versus mortality analysis (Figure 2D and supplemental Table 
15), show the same four strategies on the frontier (Fib-4+VCTE [307, $690], VCTE+LB [285, 
$1,060], VCTE [279, $1,347] and LB [270, $2,183]) than those results based on low cirrhosis 
prevalence.      
High prevalence of cirrhosis (4%). Baseline results for the high prevalence of cirrhosis closely 
parallel those from low and intermediate prevalence (Table 4, Figure 2E). The same three 
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strategies (Fib-4 followed by either VCTE, MRE or LB) comprise the 3 least costly strategies, with 
accuracies ranging from 87.5% for Fib-4+VCTE to 96.1% for Fib-4+LB. As expected due to a 
higher proportion of cirrhosis, both costs per person and cost per correct diagnosis are higher than 
in the two previous prevalence scenarios, ranging respectively from $1,024 for Fib-4+VCTE to 
$1,441 for Fib-4+LB and from $1,170 for Fib-4+VCTE to $1,500 for Fib-4+LB. Fib-4 alone 
remains the least accurate  strategy (55.9%). Similar to findings under conditions of intermediate 
prevalence, the same three frontier strategies appear on the efficiency frontier, with ICERs ranging 
from $2,921 to $5,956 per additional correctly diagnosed case. Cost versus mortality analysis also 
show the same four diagnostic strategies on the frontier, with Fib-4+VCTE displaying highest 
mortality (613) followed by VCTE+LB (568), VCTE (559) and LB (540) (Figure 2F and 
supplemental Table 16).   
Sensitivity analyses. 
Prevalence of cirrhosis. When the prevalence of cirrhosis is extended to as high as 12%, cost per 
correct diagnosis increases for all strategies, as shown in Supplemental Figure 2. The largest cost 
increases are observed for Fib-4, VCTE, and MRE, with respective increases of $4,276, $4,030, and 
$3,732 from the previously considered low prevalence. Cost increases are the lowest for the two 
NITs of FIB-4+VCTE and FIB-4+MRE, with respective increases of $2,364 and $2,298 from the 
previously considered low prevalence.  
Test characteristics. Results of one-way sensitivity analyses on each test’s sensitivity and 
specificity are shown in Supplemental Figure 3A-D. Within the ranges of test characteristics, the 
general pattern of cost per correct diagnosis are comparable: negligible effects of sensitivity on 
either individual or combination strategies, negligible effects of specificity for combination 
strategies, and a modest cost reduction for individual tests as specificity increases.  
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Test costs. Results of 8 one-way sensitivity analyses on the cost of each test are shown in 
supplemental Table 17 and in supplemental Figure 4. Note that the baseline values were set at 
Medicare average price supplemental Table 4, i.e., $0, $1,411, $150.34 and $544.18 for Fib-4 LB, 
VCTE and MRE. For the one-way sensitivity analysis on each cost parameter, alternative cost 
values are based on the national average for facility fees among hospital-based clinics and the 90th 
percentile for charges submitted by hospital-based clinics; see supplemental Table 17.  
Considering sensitivity in the tradeoff of cost vs accuracy with respect to the cost 
parameters, supplemental Table 18 shows the percentage of times (9 in total) each strategy is on 
efficiency frontier.  Fib-4+VCTE, Fib-4+MRE, and Fib-4+LB are on efficiency frontier in 89% of 
the scenarios, respectively. In contrast, MRE+LB and VCTE+LB are on the frontier only when the 
costs of MRE and LB are high, and in 11% of the scenarios, respectively. The Tornado plot of cost 
per correct diagnosis shows Fib-4+VCTE to be the least costly strategy with a range of $397 to 
$590, whereas LB and MRE, each alone, are the two most costly strategies (supplemental Figure 
4). 
DISCUSSION 
Since cirrhosis is the major determinant of long-term morbidity and mortality in patients 
with NAFLD, there is a critical need to detect cirrhosis before complications occur, which are 
associated with a high mortality and increased healthcare utilization. The sequential combination of 
two NITs or a NIT test plus liver biopsy may detect cirrhosis more accurately,9, 10 however, whether 
these approaches are cost-effective is unknown. This study suggests that the use of Fib-4 followed 
by VCTE is likely the most cost-effective strategy for screening or detecting cirrhosis among 
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patients with NAFLD either in the setting of general population, or specialty clinics and tertiary 
referral centers. Other diagnostic strategies such as Fib-4 followed by either MRE or LB, and 
VCTE followed by LB are likely cost-effective approaches but might have higher costs than Fib-4 
followed by VCTE across all cirrhosis prevalence scenarios. 
There is a current knowledge gap regarding the cost-effectiveness of single versus 
sequential combined screening strategies for cirrhosis in NAFLD. Our findings support previous 
work suggesting that the use of sequential combination tests is more cost-effective than are single 
tests.9, 10, 24
Among the 5 combination tests compared in the base case analysis, Fib-4+VCTE ranks first 
due to the best combination of cost per correct diagnosis and diagnostic accuracy. Fib-4+MRE 
ranks second, with higher percentage of people correctly classified (ranging from 90.6%-92.4% vs. 
87.5%-89.3% with Fib-4+VCTE) but higher costs. The combinations of Fib-4+LB or VCTE+LB 
ranked third and fourth, respectively, across all cirrhosis prevalence settings. Although both 
combinations yield higher accuracy, they have higher costs per correct diagnosis as compared with 
either FIB-4+VCTE or Fib-4+MRE. Finally, the combination of MRE+LB ranked fifth among all 
combination tests.  
Overall, using MRE together with either LB or Fib-4 moderately increases overall costs and 
therefore reduces cost-effectiveness as compared to combinations that include VCTE plus Fib-4 or 
LB. The results highlight the importance of diagnostic accuracy, with costs being more influential 
on strategies including MRE. This finding suggests that, due to its point-of-care availability and 
more affordable cost, a VCTE based strategy may be the most attractive approach when considering 
potential population-based screening program as well as in the setting of specialist clinics.   
15 
If the goal is to avoid liver biopsy, Fib-4+VCTE is a very cost-effective strategy among 
NITs. This strategy could be particularly important in the community setting or in resource-limited 
areas where Fib-4+VCTE can be used to screen for cirrhosis among patients with NAFLD. In the 
setting of higher prevalence of cirrhosis such as referral centers, either Fib-4 together with VCTE or 
MRE may be useful tools for detecting cirrhosis.      
This analysis evaluated the cost-effectiveness of a comprehensive list of screening strategies 
for cirrhosis diagnosis in the context of NAFLD with varying prevalence of cirrhosis.  Other 
strengths of this study include: (1) using liver biopsy as the reference standard for cirrhosis diagnosis 
and blood- and imaging-based tests, (2) simulated distribution of outcomes and its treatments 
considering real-world data, and (3) assessment of uncertainty including a wide range of cirrhosis 
prevalence, sensitivity and specificity values, as well as assuring the statistical confidence in 
comparative studies by running the microsimulation with a sufficiently large cohort multiple times 
for each strategy.    
This analysis has limitations as well, including: (1) results are based on the U.S. costs and 
may not generalize to other healthcare systems; (2) MRI costs were used as a proxy for MRE;  
MRE is a relatively new diagnostic imaging technology without a CPT code for insurance 
reimbursement currently, although it is being used often in the United States for routine clinical 
care; (3) since the sensitivity and specificity of non-invasive tests in the context of a primary care 
setting are not available, this information was extrapolated from studies conducted at tertiary 
referral centers; (4) in order to minimize the complexity of our analysis, we simplified some aspects 
of our decision tree such as single time testing and binary cut-off values for VCTE and MRE and 
assuming that causes of death are limited to variceal bleeding and HCC during first five years of 
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follow-up; and (5) finally, our cost-effectiveness is not a traditional one, i.e., cost per life-year save 
or cost per quality adjusted life year. We used cost  per correct diagnosis as a proxy for cost-
effectiveness for several reasons. such that the risk of hard outcomes such as mortality due to 
hepatic and cardiovascular events is not common. Second, not well-described are the natural history 
of cirrhosis due to NAFLD and the effects of identifying and treating large esophageal varices and 
hepatocellular carcinoma in this setting. 
In conclusion, this study suggests that Fib-4 followed by either VCTE, MRE or LB are cost-
effective strategies for identifying cirrhosis in populations where the prevalence of cirrhosis varies 
between 0.27%-4%. Compared to the combination of FIB-4 and VCTE, the ICERs were higher for 
the combination of  FIB-4 and MRE were lower than for the combination of FIB-4 and liver biopsy. 
If the goal is to avoid liver biopsy, the combination of Fib-4+VCTE with its lower costs and 
accessibility is likely the preferred strategy for the screening of cirrhosis in the setting of general or 
community-based populations.    
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Table 1. Model parameters, base-case values and ranges. 
Parameter Value Range 
(minimun-maximun) 
Reference 
Prevalence of biopsy-confirmed cirrhosis 
 Population-based 0.27% - 12
  Community-based 2% 11
Prevalence of esophageal varices 34.7% - 18
Prevalence of large or high-risk varices 11.5% - 20
3-year rate of varices progression 34% - 21
Annual incidence of esophageal varices 4.4% - - 
2-year risk of bleeding with primary prophylaxis 17% 14%-20% 22
2-year risk of bleeding without primary prophylaxis 31% 18%-60% 23, 25
5-year mortality due to variceal bleeding 20% 20%-80% 17
Annual incidence of hepatocellular carcinoma 2.5% - 2
3-year mortality due to hepatocellular carcinoma 49.2% 46.4%-77.2% 16
Liver biopsy *  26
Sensitivity  93% 89%-100% 
Specificity  95% 92%-100% 
Fib-4 index 7
Optimal high cutoff (>3.25) 
Sensitivity 38% 35%-41% 
Specificity 97% 95%-100% 
Optimal low cutoff (<1.30) 
Sensitivity 84% 74%-85% 
Specificity 69% 65%-71% 
Indeterminate results 32% 12%-46% 7
Magnetic resonance elastography 
Optimal cutoff for cirrhosis (4.7) 
27, 28
Sensitivity 80% 60%-97% 
Specificity 86% 84%-93% 
Failure rates 4% 4%-6% 14, 15
21 
Vibration controlled transient elastography 4, 13, 27, 28
Optimal cutoff for cirrhosis (11.8) 
Sensitivity 80% 78%-95% 
Specificity 81% 85%-89% 
Failure rates 7.1% 3.5%-50% 4, 13
* Considering optimal liver tissue specimens (≥ 2.5 cm in length and ≥ 10 portal tracts)
Specificity and sensitivity for cirrhosis were calculated using pooled data from published studies. 
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Table 2. Accuracy and cost-effectiveness of different diagnostic strategies. A microsimulation analysis based on 100,000 NAFLD patients considering a 







































No test N/A N/A N/A N/A 10 N/A 25 5 46 - 
Fib-4+VCTE 116 89,145 89.3% 32.2% 401 450 21 5 42 Least costly 
Fib-4+MRE 120 92,272 92.4% 35.4% 491 531 22 5 42 2,864 
VCTE+LB 187 91,769 92.0% 34.9% 612 667 19 4 40 4,454 
Fib-4+LB 145 97,592 97.7% 40.7% 729 747 21 5 42 Dominated 
MRE+LB 193 95,071 95.3% 38.2% 888 932 19 4 40 Dominated 
VCTE 201 75,046 75.2% 18.2% 900 1,197 18 4 39 Dominated 
Fib-4 70 56,966 57.0% Reference 908 1,592 21 5 41 Dominated 
MRE 207 82,337 82.5% 25.5% 1,109 1,344 19 4 39 Dominated 
LB 251 94,744 95.0% 38.0% 1,663 1,751 17 4 37 Dominated 
Abbreviations: VCTE, vibration controlled transient elastography; LB, liver biopsy; MRE, Magnetic resonance elastography; HCC, hepatocellular 
carcinoma; ICER, incremental cost effectiveness ratio.  
Total mortality includes mortality cases from variceal bleeding, HCC and other than bleeding or HCC.   
Strategies are listed in order of increasing costs. 
* It represents difference between tests and the reference strategy (Fib-4).
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Table 3. Accuracy and cost-effectiveness of different diagnostic strategies. A microsimulation analysis based on 100,000 NAFLD patients 







































No test N/A N/A N/A N/A 77 N/A 187 41 344 - 
Fib-4+VCTE 860 87,599 88.5% 32.0% 690 780 158 30 307 Least costly 
Fib-4+MRE 888 90,671 91.6% 35.1% 781 853 159 30 307 2,918 
Fib-4+LB 1,076 95,899 97.0% 40.5% 1,060 1,093 155 29 302 5,156 
VCTE+LB 1,382 90,177 91.6% 35.1% 1,060 1,158 142 23 285 Dominated 
Fib-4 517 55,978 56.5% Reference 1,236 2,187 153 28 300 Dominated 
MRE+LB 1,428 93,421 94.8% 38.4% 1,329 1,401 142 24 285 Dominated 
VCTE 1,486 73,744 75.2% 18.7% 1,347 1,791 138 22 279 Dominated 
MRE 1,536 80,909 82.4% 26.0% 1,557 1,889 139 22 280 Dominated 
LB 1,860 93,100 95.0% 38.5% 2,183 2,299 131 19 270 Dominated 
Abbreviations: VCTE, vibration controlled transient elastography; LB, liver biopsy; MRE, Magnetic resonance elastography; HCC, hepatocellular 
carcinoma; ICER, incremental cost effectiveness ratio.  
Total mortality includes mortality cases from variceal bleeding, HCC and other than bleeding or HCC.   
Strategies are listed in order of increasing costs. 
* It represents difference between tests and the reference strategy (Fib-4).
24 
Table 4. Accuracy and cost-effectiveness of different diagnostic strategies. A microsimulation analysis based on 100,000 NAFLD patients considering a 







































No test N/A N/A N/A N/A 157 N/A 373 81 686 - 
Fib-4+VCTE 1872 85659 87.5% 31.7% 1024 1170 316 60 613 Least costly 
Fib-4+MRE 1863 88735 90.6% 34.7% 1114 1230 318 60 613 2,921 
Fib-4+LB 2152 93942 96.1% 40.2% 1441 1500 310 57 603 5,956 
VCTE+LB 3029 88073 91.1% 35.2% 1579 1733 283 47 568 Dominated 
Fib-4 2224 53645 55.9% Reference 1616 2892 306 56 599 Dominated 
MRE+LB 3006 91366 94.4% 38.5% 1840 1950 284 47 569 Dominated 
VCTE 3237 71975 75.2% 19.3% 1861 2474 276 44 559 Dominated 
MRE 3221 79109 82.3% 26.5% 2077 2523 277 44 559 Dominated 
LB 3720 91200 94.9% 39.1% 2777 2925 262 39 540 Dominated 
Abbreviations: VCTE, vibration controlled transient elastography; LB, liver biopsy; MRE, Magnetic resonance elastography; HCC, hepatocellular 
carcinoma; ICER, incremental cost effectiveness ratio.  
Total mortality includes mortality cases from variceal bleeding, HCC and other than bleeding or HCC.   
Strategies are listed in order of increasing costs. 
* It represents difference between tests and the reference strategy (Fib-4).
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FIGURE LEGENDS 
Fig. 1. Model structure. 
(A) Decision analytic tree using single tests.
(B) Decision analytic tree using sequential tests.
(C) Microsimulation of patients’ assessment after receiving a diagnosis of cirrhosis.
Abbreviations: VCTE, vibration controlled transient elastography; MRE, magnetic resonance 
elastography; C, cirrhosis; NC, no cirrhosis; CD, correctly diagnosed; MD, misdiagnosed; CR, 
correctly ruled out; UD, undiagnosed; HCC, hepatocellular carcinoma; EV, esophageal varices; 
EVL, endoscopic variceal ligation; OLT, orthotopic liver transplantation; NSBB, nonselective 
beta-blockers; EGD, esophagogastroduodenoscopy.    
Fig. 2. Incremental cost-effectiveness or cost-mortality “Frontier” of 9 diagnostic strategies. 
(A) Cost per person vs accuracy considering a cirrhosis prevalence of 0.27%.
(B) Cost per person vs mortality considering a cirrhosis prevalence of 0.27%.
(C) Cost per person vs accuracy considering a cirrhosis prevalence of 2%.
(D) Cost per person vs mortality considering a cirrhosis prevalence of 2%.
(E) Cost per person vs accuracy considering a cirrhosis prevalence of 4%.
(F) Cost per person vs mortality considering a cirrhosis prevalence of 4%.
The points on the line are the strategies on the frontier and considered dominating strategies, and 
points below the line are the less cost-effective strategies. 
Abbreviations: VCTE, vibration controlled transient elastography; LB, liver biopsy; MRE, 
magnetic resonance elastography.  









